July 11th 2018EP. 1: Diagnosing Chronic Lymphocytic Leukemia
July 11th 2018EP. 2: Identifying Mutational Status in CLL
July 11th 2018EP. 3: CLL: When to Initiate Frontline Therapy
July 11th 2018EP. 4: Clinical Significance of Upfront Ibrutinib in CLL
July 11th 2018EP. 5: CLL: Data Impact and Sequencing Approach
July 11th 2018EP. 6: Rationale for Novel Combinations in CLL
July 11th 2018EP. 7: CLL: Unmet Needs and Future Outlook
July 11th 2018EP. 8: CLL: Addressing Treatment Paradigms and Unmet Needs
July 11th 2018EP. 9: Diagnostic Factors and Treatment Changes in CLL
July 11th 2018EP. 10: Coverage and Clinical Support in CLL Treatment
July 11th 2018EP. 11: CLL: Managed Care Outlook on Clinical Trial Data
July 11th 2018EP. 12: Clinical Impact of the RESONATE-2 Trial in CLL
July 11th 2018EP. 13: CLL: Treatment Pathway Changes and Cost Effectiveness
July 11th 2018EP. 14: Role of Real-World Data and Sequencing in CLL
July 11th 2018EP. 15: CLL: Impact of Combination Therapies on Managed Care
July 11th 2018EP. 16: Combination Therapy Values and Future Outlook in CLL
July 11th 2018EP. 17: The Biology and Diagnosis of CLL
July 11th 2018EP. 18: Initiating Frontline Therapy in CLL
July 11th 2018EP. 19: CLL: Rationale for Ibrutinib and Sequencing
July 11th 2018EP. 20: CLL: Combination Strategies and Unmet Needs
